Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026 - Summary - MDSpire

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026

  • By

  • Norio Akuta

  • Tomomi Kogiso

  • Kenichi Ikejima

  • Motoyuki Otsuka

  • Takumi Kawaguchi

  • Miwa Kawanaka

  • Hirokazu Takahashi

  • Nobuharu Tamaki

  • Hayato Nakagawa

  • Hayato Hikita

  • Hideki Fujii

  • Kanji Yamaguchi

  • Masato Yoneda

  • Kazuyoshi Kon

  • Akira Uchiyama

  • Yuya Seko

  • Sadatsugu Sakane

  • Ryuta Shigefuku

  • Naoto Fujiwara

  • Michihiro Iwaki

  • Takashi Kobayashi

  • Takuya Adachi

  • Yasuto Takeuchi

  • Tsubasa Tsutsumi

  • Dan Nakano

  • Kaoru Shibayama

  • Noriyo Urata

  • Hisamitsu Miyaaki

  • Hidekatsu Kuroda

  • Masahiro Koseki

  • Hirohito Sone

  • Yasuhiro Matsubayashi

  • Keisuke Kakisaka

  • Atsushi Takai

  • Kazuo Notsumata

  • Masataka Seike

  • Yoshiyuki Takei

  • Yoshifumi Takeyama

  • Susumu Eguchi

  • Sumio Watanabe

  • Hajime Isomoto

  • Hiroshi Yotsuyanagi

  • Takao Itoi

  • Tetsuo Takehara

  • Satoshi Mochida

  • May 13, 2026

  • 0 min

Share

Objective:

To provide updated clinical practice guidelines for the diagnosis and management of MASLD, reflecting recent evidence and a revised understanding of the disease, emphasizing their importance in clinical practice.

Key Findings:
  • The prevalence of MASLD is approximately 30% globally, with higher rates in men, highlighting the need for targeted interventions.
  • Patients with MASLD have a significantly increased risk of liver-related events, including a 17-fold higher risk of hepatocellular carcinoma compared to matched controls, necessitating close monitoring.
  • MASLD is associated with increased risks of cardiovascular disease, chronic kidney disease, and extrahepatic malignancies, underscoring the systemic nature of the disease.
Interpretation:

The MASLD concept replaces NAFLD, emphasizing the metabolic underpinnings of the disease and the importance of hepatic fibrosis in prognosis, which may influence treatment strategies.

Limitations:
  • Limited evidence on the prevalence of MASLD in children, which may affect understanding of the disease's impact across age groups. Potential selection bias in histology-based studies affecting MASH prevalence estimates should be considered.
Conclusion:

The guidelines emphasize the need for a comprehensive approach to diagnosing and managing MASLD, integrating noninvasive assessments and updated treatment recommendations, which are crucial for improving patient outcomes.

Original Source(s)

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026

  • by Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida

  • May 13, 2026

Related Content

6 takeaways from STAT’s investigation into the U.S. alcohol epidemic

Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling

To Fix or Not to Fix: Effect of Gastropexy on Esophageal Manometric Values Post Laparoscopic Sleeve Gastrectomy